Showing papers on "Derivative (chemistry) published in 1987"
Patent•
29 Jun 1987
TL;DR: A poly-label oligonucleotide having a plurality of labels, comprising labels carried on a polylysine and having the poly-lysine introduced on the extension from 5'- and/or 3'-end through phosphate group is useful as a probe for hybridization as mentioned in this paper.
Abstract: A poly-labelled oligonucleotide having a plurality of labels, comprising labels carried on a polylysine and having the polylysine introduced on the extension from 5'- and/or 3'-end through phosphate group is useful as a probe for hybridization.
411 citations
170 citations
125 citations
Patent•
08 Dec 1987TL;DR: A ruthenium-phosphine complex having a 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl or its derivative as a ligand and carboxyl groups bonded to the ruthensium atom thereof is disclosed in this paper.
Abstract: A ruthenium-phosphine complex having a 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl or its derivative as a ligand and carboxyl groups bonded to the ruthenium atom thereof is disclosed. The complex is inexpensive and exhibits excellent performances as a catalyst for various organic syntheses, and particularly for asymmetric hydrogenation.
105 citations
83 citations
TL;DR: The Paraquat dication forms a 1:1 molecular inclusion complex both in acetone solution and in the solid state with the bisparaphenylene-34-crown-10 derivative (BPP34C10) as a result of intra-complex stabilisation from charge transfer interactions as well as from hydrogen and electrostatic bonding.
Abstract: The Paraquat dication forms a 1:1 molecular inclusion complex both in acetone solution and in the solid state with the bisparaphenylene-34-crown-10 derivative (BPP34C10) as a result of intra-complex stabilisation from charge transfer interactions as well as from hydrogen and electrostatic bonding.
82 citations
72 citations
64 citations
Patent•
09 Oct 1987
TL;DR: In this article, an optically active lactic acid derivative (A) of liquid crystal nature represented by formula I (wherein R is a 1-16C alkyl; m is 1-2; the mark * is an asymmetric carbon atom; X is a group of formula II; R is 4-16 C alkyls; n is 1 or 2; a is 0 or 1).
Abstract: PURPOSE:To obtain a liquid crystal composition which has a smectic-C phase extending through a lower-temperature side and excellent speed of response, by mixing a specified optically active lactic acid derivative of liquid crystal nature with a specified optically active liquid crystal compound. CONSTITUTION:An optically active lactic acid derivative (A) of liquid crystal nature represented by formula I (wherein R is a 1-16C alkyl; m is 1-2; the mark * is an asymmetric carbon atom; X is a group of formula II; R is a 4-16C alkyl; n is 1 or 2; a is 0 or 1) is mixed with an optically active liquid crystal compound (B) of formula III (wherein p is 4-16; q is 1 or 2; r is 1 or 2; Z is O or S; R is an optically active 5-12C alkyl) to give an objective liquid crystal composition. It is preferred that a liquid crystal compound of formula I be produced via an optically active substance of formula IV (wherein X is OH, a halogen, etc.), and a liquid crystal compound of formula II via an optically active substance of formula V (wherein Y is OH, a halogen, etc.).
51 citations
Patent•
03 Jun 1987
TL;DR: A process based on a polymerization reaction of an ethylenically unsaturated monomeric compound in a hydroxylated polyester resulting from a polyesterification re-action of a polycarboxylic acid or a derivative thereof is described in this article.
Abstract: A process based on a polymerization reaction of an ethylenically unsaturated monomeric compound in a hydroxylated polyester resulting from a polyesterification reaction of a polycarboxylic acid or a derivative thereof, with polyhydroxylated compounds containing from 0.001 to 0.5 mole % of an unsaturated monomer over the total of acid monomers comprising it; the amount of monomeric compounds ranges from 5% to 40% by weight of the reactants.
51 citations
TL;DR: In this paper, the authors describe the formation and structure of complex structures in terms of the apG and NH 3 2 (ApG) 2 O(H 2 O)(ApG).
Abstract: Formation et structure de complexes tels que cis-[Pt(NH 3 ) 2 (ApG)] + et [Pt(NH 3 ) 2 (H 2 O)(ApG)] +
TL;DR: In this article, the hitherto unknown 2,3-dimethylene-2, 3-dihydrothiophene and a substituted derivative have been prepared in solution and trapped as Diels-Alder adducts in good to excellent yields.
Patent•
07 Sep 1987
TL;DR: In this article, a conjugate comprising a magnetic material and a physiologically active substance bound to each other through a polyethylene glycol derivative is presented. But this conjugation does not consider the effect of magnetic properties.
Abstract: Disclosed is a conjugate comprising a magnetic material and a physiologically active substance bound to each other through a polyethylene glycol derivative, and a conjugate comprising a magnetic material and a polyethylene glycol derivative bound to each other. According to the present invention, a bioreactor enabling application to or recovery of physiologically active substances under liquid state by utilizing the magnetic properties is provided.
Patent•
02 Jun 1987
TL;DR: In this article, a stabilized benzimidazoleamide derivative is defined, where each benzimdazole derivative is in amorphous form or present in contact with a basic material.
Abstract: A stabilized physiologically active benzimidazole derivative having the formula (I): wherein R¹ is hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a fluoroalkyl group having 1 to 6 carbon atoms, a cycloalkyl group, phenyl group or an aralkyl group, R² is hydrogen atom or a lower alkyl group, or R¹ and R² together with the adjacent nitrogen atom form a ring, and each of R3a, R3b, R4a, R4b and R4c independently is hydrogen atom, a halogen atom, a flouroalkyl group having 1 to 6 carbon atoms, a lower alkyl group, a lower alkoxy group, a lower alkoxycarbonyl group or an amino group. The stabilized benzimdazole derivative is in amorphous form or present in contact with a basic material.
TL;DR: In this article, a formal total synthesis of acosamine and the preparation of N-acylated daunosamine derivative 4 from a common intermediate is described, and the synthesis of Daunosamines is described.
TL;DR: A hydroxybenzofuran derivative related to part of the avermectin structure has been prepared by a free radical cyclisation as mentioned in this paper, which has been shown to be stable in the presence of a free-radical cycle.
TL;DR: In this article, the reaction of SnCl2 with Li[Si(SiMe3)3] · 3THF in Et2O at − 78°C affords [(Me3Si)3Si]2Sn(μ-Cl)Li(THF)3, which has been established by X-ray crystallography.
IBM1
Patent•
19 Aug 1987
TL;DR: A chemiluminescent acridinium derivative of the formula I in which R is hydrogen, an alkyl, alkenyl, or alkynyl radical having 1 to 10 carbon atoms, a benzyl or aryl group, R and R is a reactive group which under mild conditions can selectively form a bond with amino, carboxyl, thiol or other functional groups in substances of biological interest as discussed by the authors.
Abstract: A chemiluminescent acridinium derivative of the formula I in which R is hydrogen, an alkyl, alkenyl or alkynyl radical having 1 to 10 carbon atoms, a benzyl or aryl group, R and R are hydrogen, an alkyl group having 1 to 4 carbon atoms, a substituted or unsubstituted amino group, a carboxyl, C1-C4-alkoxy, cyano or nitro group or halogen, R represents a radical in which a sulphonamide group is bonded directly to the carbonyl group via the nitrogen or represents a thioalkyl or thioaryl radical of the formula II - S - X - R (II) where X is a branched or unbranched aliphatic or aromatic group, which can also contain hetero atoms and R is a reactive group which under mild conditions can selectively form a bond with amino, carboxyl, thiol or other functional groups in substances of biological interest, and A is an anion impairing chemiluminescence; and its use in luminescence immunoassays.
Patent•
10 Apr 1987
TL;DR: A 2-phenoxypyrimidine derivative having the formula: wherein R1 is a formyl group, a dimethoxymethyl group pr -COOR4 (wherein R4 is a hydrogen atom, a lower alkyl group and a benzyl group as mentioned in this paper ).
Abstract: A 2-phenoxypyrimidine derivative having the formula: wherein R1 is a formyl group, a dimethoxymethyl group pr -COOR4 (wherein R4 is a hydrogen atom, a lower alkyl group, a benzyl group, an alkali metal atom, an alkaline earth metal atom or an organic ammonium group), R2 is a chlorine atom, a methyl group, a methoxy group or a difluoromethoxy group, R3 is a methyl group or a methoxy group, X is a halogen atom, a lower alkyl group, a lower alkoxy group, an amino group, a hydroxyl group, a nitro group or a cyano group, and n is 1 or 2.
TL;DR: Bromination of the 7-lithiotriazolopyridines (7) and (10) gave small yields of 7-bromotriazolatemorphine (8), 5-trimethylsilyltriaxoloisoquinoline (5) and its lithium derivative as discussed by the authors.
Abstract: Bromination of the 7-lithiotriazolopyridines (7) and (10) gave small yields of the 7-bromotriazolopyridines (8) and (11). Some ring opening was observed with the lithium derivative (7); ring opening was a major reaction when bromine reacted with 5-lithiotriazoloisoquinoline (15) or with the 7-trimethylsilyltriazolopyridine (20). Good yields of 7-bromotriazolopyridines (8) and (18) and of 5-bromotriazoloisoquinoline (19) were obtained from the appropriate lithio derivative and dibromotetrachloroethane. The properties of 5-trimethylsilyltriazoloisoquinoline and its lithium derivative are reported; protodesilylation has been achieved with compounds (25)–(28).
Patent•
25 Aug 1987
TL;DR: In this paper, a novel vitamin D derivative, 1 alpha, 25-dihydroxy-22Z-dehydrovitamin D2, is described by unexpectedly high ability to raise serum calcium levels The compound could therefore, find ready application as a substitute for vitamin D or its metabolites in the treatment of metabolic bone diseases or in other known applications.
Abstract: The invention provides a novel vitamin D derivative, 1 alpha ,25-dihydroxy-22Z-dehydrovitamin D2 The compound is characterized by unexpectedly high ability to raise serum calcium levels The compound could therefore, find ready application as a substitute for vitamin D or its metabolites in the treatment of metabolic bone diseases or in other of their known applications
TL;DR: The structure of citorellamine has been revised and confirmed by total synthesis to be 2 instead of 1 as discussed by the authors, which is the same as the structure of CITAS.
TL;DR: An octa-alkylsubstituted derivative of dihydroxo-tin(IV) phthalocyanine is shown to form columnar liquid crystals as mentioned in this paper, which leads to a spinal columnar mesophase by formation of oxystannyl links between the macrocyclic units.
Abstract: An octa-alkylsubstituted derivative of dihydroxo-tin(IV) phthalocyanine is shown to form columnar liquid crystals; polycondensation of the dihydroxo-tin(IV) derivative leads to a spinal columnar mesophase by formation of oxystannyl links between the macrocyclic units
TL;DR: It is proposed that D-penicillamine may exert its therapeutic effect in the treatment of rheumatoid arthritis by scavenging HOCl and by converting myeloperoxidase to Compound III, which is inactive in the formation of HOCl.
TL;DR: In this article, the optically active basic skeleton of quinocarcin, iminoazepinoisoquinoline 1 was efficiently synthesized starting from phenylalanine and glutamic acid derivative.
TL;DR: The relationship between chemical structure and sandalwood fragrance in a series of four isomers of 8-tert-butylbicyclo[4.4.0]decan-3-ol (4a-d), the unsaturated analogue 5 and the methyl-substituted derivative 17 has been examined as mentioned in this paper.
Abstract: The relationship between chemical structure and sandalwood fragrance in a series of four isomers of 8-tert-butylbicyclo[4.4.0]decan-3-ol (4a-d), the unsaturated analogue 5 and the methyl-substituted derivative 17 has been examined. The sandalwood fragrance of decalol 4c suggests a potentially new class of compounds having a sandalwood odour.